Physician profile
Tamer Refaat
NPI 1023429636
$151,077.25
in general payments reported to CMS, 2019-2025
7 companies · $630 in 2025
The $630 reported for 2025 was more than what 78% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,500 · 2021: $147K · 2022: $241 · 2023: $229 · 2024: $296 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609 · Travel and Lodging: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.14 |
| Travel and Lodging | $546.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $146,150.00 | 2021 | |
| Novocure INC. | $2,500.00 | 2020 | |
| Viewray Technologies INC | $909.75 | 2021 | |
| Siemens Medical Solutions USA, INC. | $649.53 | 2024-2025 | Varian Ethos Treatment Planning, Truebeam |
| Carl Zeiss Meditec USA, INC. | $455.76 | 2021-2025 | Intrabeam 600 |
| Histosonics, INC. | $256.76 | 2024 | |
| Elekta, INC. | $155.45 | 2022-2023 | Elekta Medical Linear Accelerator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamer Refaat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.